Clascoterone (Breezula) for Hair Loss: What the Studies Really Show

FEATURE – A new name is making waves in the hair loss world: Clascoterone, or Breezula (its commercial name). The company Cosmo is claiming this molecule could become an effective treatment for androgenetic alopecia — sometimes touted as a future topical alternative to finasteride. But what do the studies actually show?

Table of Contents

1. What is Clascoterone / Breezula?
2. Why Cosmo sees it as a major breakthrough against hair loss
3. What the early studies show (Phase II)
4. The large Phase III trials (SCALP 1 & 2)
5. Breezula vs Minoxidil vs Finasteride
6. Limitations, open questions and timeline
7. Should you wait for Clascoterone before treating your hair loss?
8. Key takeaways
9. A non-pharmaceutical alternative available today
10. Sources

1. What is Clascoterone, exactly?

A topical anti-androgen

Clascoterone — sold under the brand name Breezula — is a molecule that locally blocks the action of androgenic hormones (such as DHT) in the skin. It is what's known as a topical anti-androgen: rather than acting systemically like an oral finasteride tablet, it works directly where it is applied, in a similar fashion to minoxidil.

Already approved for acne

Clascoterone is already authorised for facial acne treatment under the name Winlevi® (1% cream). This means two things:

• Its cutaneous safety profile is already well documented.
• Phase III clinical trial data already exists in another indication (acne).

For hair loss, it is being developed as a 5% scalp solution under the name Breezula® (clascoterone 5% solution).

2. Why Cosmo sees it as a major breakthrough against hair loss

A new way of targeting DHT

In androgenetic alopecia (hormonal hair loss), DHT — a hormone derived from testosterone — binds to receptors in the hair follicles. In genetically predisposed individuals, this causes the follicle to progressively miniaturise, producing finer and finer hair until growth stops altogether.

Finasteride, taken orally, reduces DHT production throughout the entire body. Clascoterone, by contrast, blocks DHT's action directly in the scalp, with little to no systemic effect. In theory, this means tackling the hormonal root cause locally, with a lower risk of systemic side effects.

The goal: the first approved topical anti-androgen for hair loss

Cosmo's ambition is to make clascoterone 5% the first topical anti-androgen approved for androgenetic alopecia — initially in men, and potentially in certain women further down the line. But first, the clinical evidence needs to hold up.

3. What the early studies show (Phase II)

In men: more hairs in the target area

The initial Phase II studies were conducted in men with androgenetic alopecia. Researchers divided the scalp into zones and counted hairs in a precise area known as the Target Area Hair Count (TAHC).

Results after several months of clascoterone application at various doses:

• All doses tested showed an increase in hair count in the target area compared to placebo.
• Higher doses appeared to produce better results, with TAHC gains in a similar range to some established treatments.
• The molecule was generally well tolerated locally.

In women: a signal, but mostly in younger patients

A Phase II study conducted in nearly 300 women with androgenetic alopecia produced more nuanced results. Responses were not uniformly strong across the board — but in a subgroup of women under 30, the 5% solution appeared to produce a meaningful increase in hair count in the target area.

In short: the data in women remains limited and suggests potential benefit in specific profiles, rather than across all cases.

4. The large Phase III trials (SCALP 1 & 2)

Two major studies involving over 1,400 men

To validate these early findings, Cosmo launched two large Phase III studies, known as SCALP 1 and SCALP 2:

• Approximately 1,465 men in total, all diagnosed with androgenetic alopecia.
• Randomised to receive either clascoterone 5% solution or a placebo (same vehicle, no active ingredient).
• Primary endpoint: change in TAHC after 6 months.

"Positive" results vs placebo

Cosmo has released topline results showing that:

• In both studies, clascoterone 5% outperformed placebo on TAHC.
• Announced figures point to hair gain several times greater than placebo.
• The safety profile was deemed good, with few serious side effects and no significant systemic hormonal signal.

In concrete terms: clascoterone appears capable of stimulating hair regrowth in a targeted zone — more effectively than no treatment — across a large patient population.

A word of caution: the full data isn't public yet

At this stage, what's available is mostly corporate press releases and conference presentations — not yet a full peer-reviewed publication with complete datasets, before/after photos, and subgroup analyses. The results are encouraging, but the full picture — how many hairs per cm², how it translates visually, and which patients respond best — will only become clear once the detailed papers are published.

5. Clascoterone vs Minoxidil vs Finasteride

Three very different mechanisms

Complement or replacement?

In principle, clascoterone could eventually serve as:

• A topical alternative for men who don't wish to take oral finasteride.
• A complement to other treatments, targeting the hormonal pathway directly at the scalp.
• Potentially an option for certain women, if future studies confirm the benefit.

That said, there is still no definitive head-to-head study comparing clascoterone vs finasteride vs minoxidil in real-world conditions — with patient photos and satisfaction outcomes.

6. Limitations, open questions and timeline

What we still don't know

Even with encouraging early data, several questions remain unanswered:

• Long-term efficacy (beyond 12 months).
• Effect across different scalp zones (vertex, temples, hairline).
• Detailed results in women.
• Behaviour in combination with minoxidil or other treatments.

Where does the approval process stand?

Cosmo has announced plans to file regulatory submissions with the FDA and EMA following the completion of the 12-month safety follow-up. In practice, this means clascoterone remains a treatment in development — it is not yet available in pharmacies for hair loss.

7. Should you wait for Clascoterone before treating your hair loss?

The temptation is understandable: a more targeted, modern treatment sounds appealing. But two realities are worth keeping in mind.

First, androgenetic alopecia is a progressive condition — the longer you wait, the more follicles miniaturise and the harder it becomes to reverse the damage. Second, even in an optimistic scenario, clascoterone won't be available to the general public for several years, once regulatory timelines and market launch are factored in.

Waiting indefinitely for a treatment that is still years away is not a sound strategy when hair loss is already active.

A more reasonable approach would be to:

• Consult a dermatologist to identify the type and stage of hair loss.
• Use solutions already available — pharmaceutical or cosmetic — suited to your situation.
• Follow the science… without pinning your hopes on unvalidated promises.

8. Key takeaways

• Clascoterone is a topical anti-androgen that blocks DHT directly in the scalp.
• Phase II studies and early Phase III results show hair count increases in tested areas, significantly above placebo.
• The safety profile appears favourable, with few systemic side effects reported to date.
• However, the treatment is not yet available for hair loss: regulatory decisions and full publication of results are still pending.
• In the meantime, effective non-pharmaceutical options already exist to support hair density and quality.

9. A non-pharmaceutical alternative available today

While the regulatory path for clascoterone plays out, it's entirely possible to take action now — with a non-pharmaceutical approach backed by clinical data: the OMA & ME 3-in-1 Hair Loss Protocol.

The protocol combines pre- and post-biotics, amino acids, zinc and melatonin to support the hair growth cycle and scalp balance. It comes as a serum to be applied 3 times a week for 3 months, ideally used alongside a derma roller to optimise ingredient absorption.

Discover the 3-in-1 Protocol

Important: if hair loss is rapid, extensive or unusual, the right first step is always to consult a dermatologist before modifying or adding any treatment.

10. Sources

• Cosmo / Cassiopea press releases on the SCALP 1 & 2 studies (Phase III clascoterone 5% solution).
• Winlevi® (clascoterone 1% cream) clinical data — acne indication.
• Phase II Breezula® (clascoterone solution) studies in men and women with androgenetic alopecia.
• Scientific reviews on topical anti-androgens and the pathophysiology of androgenetic alopecia.